KalVista Pharmaceuticals (KALV) Tops Q4 EPS by 10c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q4 EPS of ($0.77), $0.10 better than the analyst estimate of ($0.87).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Lennar Corp. (LEN) Misses Q2 EPS by 1c
• Aspire Biopharma to acquire automotive supplier for $30 million